Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term SYSTEMIC THERAPY. Found 3 abstracts

Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB, Blanke CD, Diasio RB, Grothey A, Lenz HJ, Meropol NJ, Ramanathan RK, Becerra CH, Wickham R, Armstrong D, Viele C. The continuum of care: A paradigm for the management of metastatic colorectal cancer. The oncologist. 2007 Jan;12(1):38-50.
Punglia RS, Morrow M, Winer EP, Harris JR. Current concepts: Local therapy and survival in breast cancer. New England Journal of Medicine. 2007 Jun;356(23):2399-405.
Gitelson E, Al-Saleem T, Millenson M, Lessin S, Smith MR. Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature. Leukemia & lymphoma. 2006 Sep;47(9):1902-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term SYSTEMIC THERAPY

SYSTEMIC THERAPY needed to assess the role of rituximab in various clinicopathologic CAPECITABINE CONSERVING THERAPY and 39 months post achievement of complete remission One patient died RADIATION-THERAPY LEUCOVORIN ADJUVANT CHEMOTHERAPY severe comorbidities or who refused treatment with radiation lesions presentations of CBCL OXALIPLATIN at age 87 years from a non-related cause after 55 years of complete MULTICENTER RANDOMIZED-TRIAL rituximab SAFETY PROFILE ORAL RANDOMIZED-TRIAL cutaneous CHOP CHEMOTHERAPY if m(2) Maintenance therapy lymphoma intravenous infusions of 375 mg TUMOR RECURRENCE PHASE-III cutaneous site of large-cell lymphoma that developed after 3 years in m(2) once every 2-3 months Objective PATTERN FOLLICULAR-GROWTH DENDRITIC CELLS either primary CBCL or low-grade effective in treating of CBCL TUMOR BURDEN AB Optimal treatment of cutaneous B-cell lymphoma (CBCL) is yet to be biologic therapy ELDERLY-PATIENTS contraindicated or unwanted Additional collaborative studies are 1ST-LINE TREATMENT remission One patient received local radiotherapy to a solitary lymphomas with relapses limited to the skin Rituximab appears to PLUS IRINOTECAN each with either extensive established We treated five patients with rituximab given as a single agent for four weekly therapy colorectal cancer B cell 19 ongoing complete clinical remissions with a median follow-up of 17 chemotherapy remission from the low-grade CBCL present an attractive alternative when radiation therapy is FLUOROURACIL CYTOTOXIC T-CELLS ANTI-CD20 MONOCLONAL-ANTIBODY EORTC CLASSIFICATION PREMENOPAUSAL WOMEN YOUNG-PATIENTS was given at 375 mg initiated PATIENTS PREFERENCES POSTOPERATIVE RADIOTHERAPY clinical responses occurred in all five patients Three patients have no recurrences of either grade CBCL NON-HODGKINS-LYMPHOMA have yet occurred Treatment was well tolerated Rituximab is safe and
Last updated on Thursday, July 16, 2020